share_log

Private Companies Among AIM Vaccine Co., Ltd.'s (HKG:6660) Largest Stockholders and Were Hit After Last Week's 5.6% Price Drop

Private Companies Among AIM Vaccine Co., Ltd.'s (HKG:6660) Largest Stockholders and Were Hit After Last Week's 5.6% Price Drop

AIM疫苗有限公司中的私營公司s (HKG: 6660) 最大的股東,在上週股價下跌5.6%後受到打擊
Simply Wall St ·  05/21 01:11

Key Insights

關鍵見解

  • AIM Vaccine's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • 52% of the business is held by the top 6 shareholders
  • Insiders have bought recently
  • AIM Vaccine擁有大量私營公司所有權,這表明關鍵決策受廣大公衆股東的影響
  • 52% 的業務由前6名股東持有
  • 內部人士最近買了

To get a sense of who is truly in control of AIM Vaccine Co., Ltd. (HKG:6660), it is important to understand the ownership structure of the business. With 34% stake, private companies possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

要了解誰真正控制了AIM疫苗有限公司(HKG:6660),了解業務的所有權結構非常重要。私人公司擁有34%的股份,是該公司的最大股份。換句話說,該集團面臨最大的上行潛力(或下行風險)。

And last week, private companies endured the biggest losses as the stock fell by 5.6%.

上週,私營公司遭受了最大的損失,股價下跌了5.6%。

Let's take a closer look to see what the different types of shareholders can tell us about AIM Vaccine.

讓我們仔細看看不同類型的股東能告訴我們關於AIM Vaccine的什麼。

ownership-breakdown
SEHK:6660 Ownership Breakdown May 21st 2024
SEHK: 6660 所有權明細 2024 年 5 月 21 日

What Does The Institutional Ownership Tell Us About AIM Vaccine?

關於AIM疫苗,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

As you can see, institutional investors have a fair amount of stake in AIM Vaccine. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of AIM Vaccine, (below). Of course, keep in mind that there are other factors to consider, too.

如您所見,機構投資者在AIM Vaccine中擁有相當數量的股份。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎地依賴機構投資者所謂的驗證。他們有時也會弄錯。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得檢查一下AIM Vaccine過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SEHK:6660 Earnings and Revenue Growth May 21st 2024
SEHK: 6660 2024年5月21日收益和收入增長

Hedge funds don't have many shares in AIM Vaccine. Looking at our data, we can see that the largest shareholder is the CEO Yan Zhou with 17% of shares outstanding. For context, the second largest shareholder holds about 17% of the shares outstanding, followed by an ownership of 8.3% by the third-largest shareholder.

對沖基金在AIM疫苗中的股份不多。從我們的數據來看,我們可以看到最大的股東是首席執行官周巖,其已發行股份的17%。就背景而言,第二大股東持有約17%的已發行股份,其次是第三大股東持有8.3%的所有權。

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

經過進一步檢查,我們發現公司一半以上的股份由前六名股東持有,這表明較大股東的利益在一定程度上被較小的股東所平衡。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。

Insider Ownership Of AIM Vaccine

AIM 疫苗的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our information suggests that insiders maintain a significant holding in AIM Vaccine Co., Ltd.. It has a market capitalization of just HK$9.5b, and insiders have HK$2.7b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有AIM疫苗有限公司的大量股份。它的市值僅爲95億港元,內部人士以自己的名義持有價值27億港元的股票。這非常重要。大多數人會說,這表明了與股東的良好一致性,尤其是在如此規模的公司中。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 32% stake in AIM Vaccine. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

公衆通常是個人投資者,持有AIM Vaccine32%的股份。儘管這個群體不一定能做主,但它肯定會對公司的運作方式產生真正的影響。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 34%, of the AIM Vaccine stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

私人公司似乎擁有AIM疫苗股票的34%。可能值得對此進行更深入的研究。如果關聯方,例如內部人士,對其中一傢俬營公司有興趣,則應在年度報告中予以披露。私營公司也可能在公司中擁有戰略利益。

Next Steps:

後續步驟:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for AIM Vaccine you should know about.

儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。例如,考慮風險。每家公司都有它們,我們已經發現了兩個你應該知道的AIM Vaccine警告信號。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但歸根結底,決定這家企業所有者的表現的是未來,而不是過去。因此,我們認爲最好看一下這份免費報告,該報告顯示了分析師是否預測了更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論